高级检索
当前位置: 首页 > 详情页

Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China [2]West China School of Medicine, Sichuan University, Chengdu, China [3]Department of Hematology, Clinical Medical College & Afliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, China [4]Department of Hematology, Chengdu Third People’s Hospital, Chengdu, Sichuan, China
出处:
ISSN:

摘要:
The benefit of high-dose melphalan followed by autologous hematopoietic stem cell transplantation (HDM-ASCT) for multiple myeloma (MM) patients with renal insufficiency (RI) is debated. A systematic review and meta-analysis were conducted to assess the safety and efficacy of HDM-ASCT in MM patients with RIs, and the findings were compared with real-world data. The study included 26 articles, 13 of which were pooled for meta-analysis. We compared three different types of MM patients with RI against MM patients with normal renal function (NRF). These patients were: MM patients with RI at the time of transplantation; MM patients with RI at the time of diagnosis; MM patients with RI at diagnosis but with NRF at transplantation. The meta-analysis indicated that MM patients with RIs conditioned with melphalan ≤ 140 mg/m2 followed by ASCT had transplant-related mortality rates comparable to those without RIs. The complete response rates post-ASCT were similar between MM patients with RIs and those with NRF. Although progression-free survival (PFS) was statistically similar between the groups, MM patients with RIs had significantly poorer overall survival (OS) than those with NRF. The real-world data supported these findings. With a reduced dose of melphalan, ASCT is safe and effective for MM patients with RI. MM patients with RI have similar complete response rates and PFS after ASCT compared to MM patients with NRF. The lower OS in MM patients with RI indicates the need for further research to improve OS in these patients.© 2024. The Author(s).

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验
第一作者:
第一作者机构: [1]Department of Hematology, Institute of Hematology, West China Hospital/ State Key Laboratory of Biotherapy and Cancer, Sichuan University, Chengdu, Sichuan, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59450 今日访问量:0 总访问量:4868 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号